A recent series of studies has shed light on potential biomarkers for the early diagnosis and monitoring of Alzheimer’s disease. These biomarkers, which can be measured through blood tests, have the potential to greatly improve the accuracy and efficiency of diagnosing and treating this devastating neurological disorder.
One such study was published in The Lancet by Scheltens and colleagues in 2021. The researchers highlighted the urgent need for biomarkers in Alzheimer’s disease and discussed the current understanding of the condition. By identifying specific biomarkers, doctors can more accurately diagnose the disease in its early stages and initiate treatment earlier.
In 2023, Swaddiwudhipong et al. published a study in Alzheimer’s & Dementia that examined pre-diagnostic cognitive and functional impairment in multiple neurodegenerative diseases. This study aimed to identify early warning signs of Alzheimer’s and other related conditions, enabling healthcare professionals to intervene before irreversible damage occurs.
In 2016, Shah et al. published a paper in Lancet Neurology that outlined research priorities to reduce the global burden of dementia by 2025. This research emphasized the importance of biomarkers in achieving this goal, as they can help identify those at highest risk of developing Alzheimer’s and enable early intervention.
Another notable study, conducted by Teunissen et al. and published in Lancet Neurology in 2022, reviewed blood-based biomarkers for Alzheimer’s disease and their potential for clinical implementation. By analyzing specific molecules in the blood, researchers hope to establish reliable and accessible diagnostic tools for Alzheimer’s disease.
Zetterberg et al. published a paper in Alzheimer’s & Dementia in 2022 that provided an update and synthesis of the literature on biofluid-based biomarkers for Alzheimer’s-related pathologies. This research aimed to consolidate existing knowledge and identify promising avenues for further exploration.
Hansson et al., in a paper published in Alzheimer’s & Dementia in 2022, presented appropriate use recommendations for blood biomarkers in Alzheimer’s disease, as outlined by the Alzheimer’s Association. These recommendations help guide healthcare professionals on the most effective and accurate use of biomarkers in diagnosing and monitoring the disease.
Nakamura et al. published a study in Nature in 2018, which discussed the use of high-performance plasma amyloid-beta biomarkers for Alzheimer’s disease. The researchers highlighted the potential of these biomarkers to accurately detect the presence of the disease and track its progression.
In a study published in Nature Medicine in 2021, Palmqvist et al. explored the prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. These findings offer hope for early detection of the disease and the possibility of implementing preventative measures to slow its progression.
Verberk et al., in a prospective cohort study published in Lancet Healthy Longevity in 2021, investigated serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people. This research aimed to identify biomarkers that could predict the likelihood of Alzheimer’s development in individuals without cognitive impairment.
Kim et al. published a study in Nature Communications in 2020, presenting a method for clinically accurate diagnosis of Alzheimer’s disease through multiplexed sensing of core biomarkers in human plasma. This innovative approach has the potential to revolutionize diagnosis and enable earlier intervention.
In a paper published in Nature Medicine in 2022, Ashton et al. discussed the differential roles of A-beta42/40, p-tau231, and p-tau217 for Alzheimer’s trial selection and disease monitoring. These biomarkers can provide valuable information for assessing the effectiveness of new treatments and monitoring disease progression.
Finally, Karikari et al. conducted a diagnostic performance and prediction modeling study published in Lancet Neurology in 2020, focusing on blood phosphorylated tau. This study illuminated the potential of this specific biomarker in diagnosing and predicting Alzheimer’s disease.
These studies collectively represent significant progress in the search for reliable biomarkers for Alzheimer’s disease. With further research and validation, these biomarkers could transform the way this disease is diagnosed and managed, leading to improved outcomes for individuals living with Alzheimer’s.